NCT01430572
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, PTEN
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with any kind of genomic alteration in either PI3K and/or PTEN of their tumor are eligible for the dose expansion cohort
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT01430572